These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 23305851)
41. Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders. Eltahla AA; Tay E; Douglas MW; White PA Antimicrob Agents Chemother; 2014 Dec; 58(12):7215-24. PubMed ID: 25246395 [TBL] [Abstract][Full Text] [Related]
42. Synthesis of potent and broad genotypically active NS5B HCV non-nucleoside inhibitors binding to the thumb domain allosteric site 2 of the viral polymerase. Pierra Rouvière C; Amador A; Badaroux E; Convard T; Da Costa D; Dukhan D; Griffe L; Griffon JF; LaColla M; Leroy F; Liuzzi M; Loi AG; McCarville J; Mascia V; Milhau J; Onidi L; Paparin JL; Rahali R; Sais E; Seifer M; Surleraux D; Standring D; Dousson C Bioorg Med Chem Lett; 2016 Sep; 26(18):4536-4541. PubMed ID: 27520942 [TBL] [Abstract][Full Text] [Related]
43. Screening of hepatitis C NS5B polymerase inhibitors containing benzothiadiazine core: a steered molecular dynamics. Nutho B; Meeprasert A; Chulapa M; Kungwan N; Rungrotmongkol T J Biomol Struct Dyn; 2017 Jun; 35(8):1743-1757. PubMed ID: 27236925 [TBL] [Abstract][Full Text] [Related]
44. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency. Beaulieu PL; Bös M; Bousquet Y; DeRoy P; Fazal G; Gauthier J; Gillard J; Goulet S; McKercher G; Poupart MA; Valois S; Kukolj G Bioorg Med Chem Lett; 2004 Feb; 14(4):967-71. PubMed ID: 15013003 [TBL] [Abstract][Full Text] [Related]
45. Characterization of aurintricarboxylic acid as a potent hepatitis C virus replicase inhibitor. Chen Y; Bopda-Waffo A; Basu A; Krishnan R; Silberstein E; Taylor DR; Talele TT; Arora P; Kaushik-Basu N Antivir Chem Chemother; 2009 Sep; 20(1):19-36. PubMed ID: 19794229 [TBL] [Abstract][Full Text] [Related]
46. A review on an update of NS5B polymerase hepatitis C virus inhibitors. Varshney J; Sharma PK; Sharma A Eur Rev Med Pharmacol Sci; 2012 May; 16(5):667-71. PubMed ID: 22774409 [TBL] [Abstract][Full Text] [Related]
47. Recent advances on the synthesis of hepatitis C virus NS5B RNA-dependent RNA-polymerase inhibitors. Zhao C; Wang Y; Ma S Eur J Med Chem; 2015 Sep; 102():188-214. PubMed ID: 26276434 [TBL] [Abstract][Full Text] [Related]
48. Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase. Koch U; Narjes F Infect Disord Drug Targets; 2006 Mar; 6(1):31-41. PubMed ID: 16787302 [TBL] [Abstract][Full Text] [Related]
49. Combination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of HCV NS5B polymerase. Harikishore A; Li E; Lee JJ; Cho NJ; Yoon HS Mol Divers; 2015 Aug; 19(3):529-39. PubMed ID: 25862642 [TBL] [Abstract][Full Text] [Related]
50. Combining 3-D quantitative structure-activity relationship with ligand based and structure based alignment procedures for in silico screening of new hepatitis C virus NS5B polymerase inhibitors. Musmuca I; Caroli A; Mai A; Kaushik-Basu N; Arora P; Ragno R J Chem Inf Model; 2010 Apr; 50(4):662-76. PubMed ID: 20225870 [TBL] [Abstract][Full Text] [Related]
52. Small molecule and biologic inhibitors of hepatitis C virus: a symbiotic approach. Del Vecchio AM; Sarisky RT Mini Rev Med Chem; 2006 Nov; 6(11):1263-8. PubMed ID: 17100638 [TBL] [Abstract][Full Text] [Related]
53. Discovery of a novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors. Stammers TA; Coulombe R; Rancourt J; Thavonekham B; Fazal G; Goulet S; Jakalian A; Wernic D; Tsantrizos Y; Poupart MA; Bös M; McKercher G; Thauvette L; Kukolj G; Beaulieu PL Bioorg Med Chem Lett; 2013 May; 23(9):2585-9. PubMed ID: 23545108 [TBL] [Abstract][Full Text] [Related]
54. Inhibitors of hepatitis C virus polymerase: synthesis and characterization of novel 2-oxy-6-fluoro-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-benzamides. Cheng CC; Shipps GW; Yang Z; Kawahata N; Lesburg CA; Duca JS; Bandouveres J; Bracken JD; Jiang CK; Agrawal S; Ferrari E; Huang HC Bioorg Med Chem Lett; 2010 Apr; 20(7):2119-24. PubMed ID: 20219368 [TBL] [Abstract][Full Text] [Related]
55. New NS5B polymerase inhibitors for hepatitis C. Legrand-Abravanel F; Nicot F; Izopet J Expert Opin Investig Drugs; 2010 Aug; 19(8):963-75. PubMed ID: 20629614 [TBL] [Abstract][Full Text] [Related]
56. Insight into the structural requirements of benzothiadiazine scaffold-based derivatives as hepatitis C virus NS5B polymerase inhibitors using 3D-QSAR, molecular docking and molecular dynamics. Zhang HX; Li Y; Wang X; Xiao ZT; Wang YH Curr Med Chem; 2011; 18(26):4019-28. PubMed ID: 21824089 [TBL] [Abstract][Full Text] [Related]
57. New therapeutic strategies in HCV: polymerase inhibitors. Gerber L; Welzel TM; Zeuzem S Liver Int; 2013 Feb; 33 Suppl 1():85-92. PubMed ID: 23286851 [TBL] [Abstract][Full Text] [Related]
58. Interference of HCV replication by cell penetrable human monoclonal scFv specific to NS5B polymerase. Thueng-in K; Thanongsaksrikul J; Jittavisutthikul S; Seesuay W; Chulanetra M; Sakolvaree Y; Srimanote P; Chaicumpa W MAbs; 2014; 6(5):1327-39. PubMed ID: 25517317 [TBL] [Abstract][Full Text] [Related]
59. Structural insights into NS5B protein of novel equine hepaciviruses and pegiviruses complexed with polymerase inhibitors. de Albuquerque PPLF; Santos LHS; Antunes D; Caffarena ER; Figueiredo AS Virus Res; 2020 Mar; 278():197867. PubMed ID: 31972246 [TBL] [Abstract][Full Text] [Related]
60. Identification of novel inhibitors of HCV RNA-dependent RNA polymerase by pharmacophore-based virtual screening and in vitro evaluation. Ryu K; Kim ND; Choi SI; Han CK; Yoon JH; No KT; Kim KH; Seong BL Bioorg Med Chem; 2009 Apr; 17(8):2975-82. PubMed ID: 19332375 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]